Nicholas Coupe
Overview
Explore the profile of Nicholas Coupe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watson R, Ye W, Taylor C, Jungkurth E, Cooper R, Tong O, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38663935
We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle...
2.
Fane M, Ecker B, Kaur A, Marino G, Alicea G, Douglass S, et al.
Clin Cancer Res
. 2023 May;
29(10):2012.
PMID: 37183634
No abstract available.
3.
Coupe N, Guo L, Bridges E, Campo L, Espinosa O, Colling R, et al.
Cell Oncol (Dordr)
. 2022 Dec;
46(2):391-407.
PMID: 36539575
Purpose: Despite recent advances, approximately 50% of patient with metastatic melanoma eventually succumb to the disease. Patients with melanomas harboring a BRAF mutation (BRAF) have a worse prognosis than those...
4.
Taylor C, Watson R, Tong O, Ye W, Nassiri I, Gilchrist J, et al.
Nat Med
. 2022 Dec;
28(12):2592-2600.
PMID: 36526722
Treatment with immune checkpoint blockade (ICB) frequently triggers immune-related adverse events (irAEs), causing considerable morbidity. In 214 patients receiving ICB for melanoma, we observed increased severe irAE risk in minor...
5.
Damato V, Berretta A, Ramanathan S, Michael S, Coupe N, Payne M, et al.
JAMA Neurol
. 2022 Jul;
79(9):949-951.
PMID: 35816342
No abstract available.
6.
Sasson S, Slevin S, Cheung V, Nassiri I, Olsson-Brown A, Fryer E, et al.
Gastroenterology
. 2021 Jun;
161(4):1229-1244.e9.
PMID: 34147519
Background & Aims: The pathogenesis of immune checkpoint inhibitor (ICI)-colitis remains incompletely understood. We sought to identify key cellular drivers of ICI-colitis and their similarities to idiopathic ulcerative colitis, and...
7.
Ye W, Olsson-Brown A, Watson R, Cheung V, Morgan R, Nassiri I, et al.
Br J Cancer
. 2021 Mar;
124(10):1661-1669.
PMID: 33723392
Background: Immune checkpoint blockers (ICBs) activate CD8 T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear....
8.
Fane M, Ecker B, Kaur A, Marino G, Alicea G, Douglass S, et al.
Clin Cancer Res
. 2020 Oct;
26(21):5709-5719.
PMID: 33097493
Purpose: Angiogenesis is thought to be critical for tumor metastasis. However, inhibiting angiogenesis using antibodies such as bevacizumab (Avastin), has had little impact on melanoma patient survival. We have demonstrated...
9.
Spiers L, Coupe N, Payne M
Rheumatology (Oxford)
. 2019 Dec;
58(Suppl 7):vii7-vii16.
PMID: 31816085
Immunotherapy has an increasing role in the management of cancer, both in metastatic disease and as an adjuvant therapy. However, sensitization of the immune system with checkpoint inhibitors comes with...
10.
Eyre T, Collins G, Gupta A, Coupe N, Sheikh S, Whittaker J, et al.
Cancer
. 2018 Oct;
125(1):99-108.
PMID: 30332497
Background: In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study...